How β-lactamases have driven pharmaceutical drug discovery: From mechanistic knowledge to clinical circumvention

Advances in Experimental Medicine and Biology

Volumn 456, Issue , 1998, Pages 71-98

  Bush, K ^a   Mobashery, S ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; SULBACTAM; TAZOBACTAM; TIMENTIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032226545     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4897-3_5     Document Type: Review

References (127)

1. An enzyme from bacteria able to destroy penicillin
2. Penicillin and cephalosporin biosynthetic genes: Structure, organization, regulation, and evolution
3. The structure of β-lactamases
4. Chemistry and biosynthesis of clavulanic acid and other clavams
5. Conjugal transfer of imipenem resistance in Bacteroides fragilis
6. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2)
7. Factors affecting methicillin resistance in Staphylococcus aureus
8. Carbapenems, a new class of beta-lactam antibiotics
9. Rapid development of ciprofloxacin resistance in methicillin-susceptible and resistant Staphylococcus aureus
10. Complementary roles of mutations at positions 69 and 242 in class A β-lactamases
11. The mechanism of catalysis and the inhibition of the Bacillus cereus zinc-dependent β-lactamase
12. Naturally occuring β-lactamase inhibitors with antibacterial activity
13. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: Observation of intermediates by electrospray ionisation mass spectrometry
14. Mass spectrometric studies on the inhibition of TEM-2 β-lactamase by clavulanic acid derivatives
15. Imipenem/cilastin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
16. Evolution of the versatile β-lactam hydrolase activity: From biosynthetic enzymes to drug resistance factors
17. Characterization of β-lactamases
18. Izumenolide - A novel beta-lactamase inhibitor produced by Micromonospora
19. A functional classification scheme for β-lactamases and its correlation with molecular structure
20. Kinetic interactions of tazobactam with β-lactamases from all major structural classes
21. Biochemical characteristics of extended broad spectrum β-lactamases
22. Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli
23. Characterization and epidemiology of beta-lactamases
24. Resistance caused by decreased penetration of β-lactam antibiotics into Enterobacter cloacae
25. Olivanic acids, a family of beta-lactam antibiotics with beta-lactamase inhibitory properties produced by Streptomyces species. I. Detection, properties and fermentation studies
26. The 3-D structure of a zinc metallo-β-lactamase from Bacillus cereus reveals a new type of protein fold
27. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid
28. Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid
29. Genetics and molecular biology of β-lactam-resistant pneumococci
30. Crystal structure of the wide-spectrum binuclear zinc β-lactamase from Bacteroides fragilis
31. In viva emergence of HIV-I variants resistant to multiple protease Inhibitors
32. National nosocomial infections surveillance system, ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States
33. The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infection
34. Penicillinase synthesis controlled by infectious R factors in enterobacteriaceae
35. The purification and properties of a penicillinase whose synthesis is mediated by an R-factor in Escherichia coli
36. Isolation and characterization of a β-lactamase-inhibitory protein from streptomyces clavuligerus and cloning and analysis of the corresponding gene
37. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases
38. The role of tyrosine 150 in catalysis of β-lactam hydrolysis by AmpC beta-lactamase from Escherichia coli investigated by site-directed mutagenesis
39. Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics
40. Recent developments in the field of beta-lactam antibiotics
41. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid
42. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase 1
43. The role of lysine-234 in β-lactamase catalysis probed by site-directed mutagenesis
44. CP-45.899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: Initial bacteriological characterization
45. Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid
46. Penicillin-sensitive enzymes in peptidoglycan biosynthesis
47. Penicillin and beyond: Evolution, protein fold, multimodular polypeptides, and multiprotein complexes
48. Serine β-lactamases and penicillin-binding proteins
49. Penicillin-binding proteins. Wall peptidoglycan assembly and resistance to penicillin: Facts, doubts and hopes
50. Resistance to cefamandole: Derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae
51. Inhibition of the mammalian β-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids
52. Plasmid-mediated β-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam
53. The disposition and metabolic fate of 14C-meropenem in man
54. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli
55. A natural polymorphism in β-lactamase is a global suppressor
56. Amino acid sequence determinants of β-lactamase structure and activity
57. The role of Ser238 and Lys240 in the hydrolysis of third-generation cephalosporins by SHV-type β-lactamases probed by site-directed mutagenesis and three-dimensional modeling
58. Sequence of PSE-2 beta-lactamase
59. Inactivation of class A β-lactamases by clavulanic acid: The role of arginine-244 in a proposed nonconcerted sequence of events
60. A structure-based analysis of the inhibition of class A β-lactamases by sulbactam
61. Comparative amino acid contents of purified β-lactamases from enteric bacteria
62. Comparative activities of the β-lactamase inhibitors YTR 830 and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads
63. amp C cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type
64. Crystal structure of Escherichia coli TEM1 β-lactamase at 1.8 Å resolution
65. Thienamycin: Development of imipenem-cilastatin
66. Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation, and physical properties
67. β-lactamase activity of renal dipeptidase against N-formimidoyl-thienamycin
68. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci
69. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens
70. Extended-spectrum and inhibitors-resistant TEM-type β-lactamases: Mutations, specificity, and three-dimensional structure
71. Molecular evolution of bacterial β-lactam resistance
72. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase
73. Augmentin (amoxicillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria
74. First characterization of inhibitor-resistant TEM (IRT) beta-lactamase in Klebsiella pneumoniae strains
75. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to β-lactam resistance
76. Evolution of an enzyme activity: Crystallographic structure at 2-Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase
77. Comparison of the substrate specificities of the β-lactamases from Klebsiella aerogenes 1082E and Enterobacter cloacae P99
78. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases
79. The Aeromonas hydrophila cphA gene: Molecular heterogeneity among Class B metallo-β-lactamases
80. Interactions between active-site serine β-lactamases and so-called β-lactamase-stable antibiotics. Kinetic and molecular modelling studies
81. Crystal-structure of 6α-(hydroxymethyl) penicillanate complexed to the TEM-1 β-lactamase from Escherichia coli: Evidence on the mechanism of action of a novel inhibitor designed by a computer-aided process
82. Structural basis for clinical longetivity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from the antibiotic-resistant bacteria
83. Evolution and dissemination of β-lactamases accelerated by generation of β-lactam antibiotics
84. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
85. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B β-lactamase
86. Quantification of the extent of attenuation of the rate of turnover chemistry of the TEM-1 β-lactamase by the α-1R-hydroxyethyl group in substrates
87. Design, synthesis and evaluation of a potent mechanism-based inhibitor for the TEM β-lactamase with implications for the enzyme mechanism
88. β-lactamase of Bacillus licheniformis 749/C at 2 Å resolution
89. β-lactamase stability of cefoxitin in comparison with other β-lactam compounds
90. Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli
91. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases
92. Penicillinase-producing gonococci in Liverpool
93. A regulatory, gene (ccaR) required for cephamycin and clavulanic acid production in Streptomyces clavuligerus: Amplification results in overproduction of both β-lactam compounds
94. Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain
95. Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae
96. Molecular epidemiology of TEM-3 (CTX-1) beta-lactamase
97. Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant
98. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia
99. Carbapenem-hydrolyzing β-lactamases
100. Characterization of IMI-I β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae
101. Clavulanic acid: A beta-lactamase inhibitor from Streptomyces clavuligerus
102. The inhibition of beta-lactamases from Gram-negative bacteria by clavulanic acid
103. Protease uninhibited
104. The β-lactamases of gram-negative bacteria and their possible physiological role
105. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid
106. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate
107. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1, a novel β-lactamase
108. Substitution of lysine at position 104 or 240 of TEM β-lactamase enhances the effect of serine-164 substitution of hydrolysis or affinity for cephalosporins and the monobactam aztreonam
109. Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12
110. Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution
111. A potent new mode of β-lactamase inhibition revealed by the 1.7 Å X-ray crystallographic structure of the TEM-1-BLIP complex
112. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria
113. The β-lactamases of gram-negative bacteria and their role in resistance to β-lactam antibiotics
114. Mechanism of turnover of imipenem by the TEM β-lactamase revisited
115. Evidence for structural elasticity of β-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime
116. Importance of antimicrobial susceptibility testing of Streptococcus pneumoniae
117. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
118. Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-D-alanine
119. Clinical isolates of Escherichia coli producing TRI β-lactamases: Novel TEM-enzymes conferring resistance to β-lactamase inhibitors
120. Structure-function relationships among wild-type variants of Staphylococcus aureus β-lactamase: Importance of amino acids 128 and 216
121. Distribution of β-lactam and β-lactone producing bacteria in nature
122. Biochemical comparison of imipenem, meropenem and biapenem: Permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases
123. Biochemical characterization of the metallo-β-lactamase Ccr A from Bacteroides fragilis TAL3636
124. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems for two Serratia marcescens isolates
125. 1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine-244 of class A β-lactamases during the course of turnover
126. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors